NCT00494182View on ClinicalTrials.gov

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 25, 2007

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Squamous Cell Carcinoma of the HypopharynxMetastatic Squamous Cell Carcinoma of the LarynxMetastatic Squamous Cell Carcinoma of the Oral CavityMetastatic Squamous Cell Carcinoma of the OropharynxRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
DRUG

Carboplatin

Given IV

DRUG

Paclitaxel

Given IV

DRUG

Sorafenib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER